BOSTON, MASS., Oct. 14, 2024 – BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its participation in the US Pharma Partnering Summit, scheduled for October 16, in Boston. BPGbio executive Vivek K. Vishnudas, Ph.D., Chief Technology Officer and R&D Site Head, will present a session titled, “A Novel and Differentiated Approach to Targeted Protein Degradation – Leveraging the Ubiquitin Conjugating Enzyme (E2) Family.” The session will highlight the latest developments in the company’s protein homeostasis program as BPGbio continues to advance the potential E2-based therapeutics in both oncology and neurology.
“Our unique approach to protein degradation through the ubiquitin conjugating enzyme (E2) family represents a significant step forward in the field of targeted protein degradation (TPD), drugging the long considered “undruggable” and distinguishing us from conventional E3 strategies, which are known to have high susceptibility to resistance mechanisms,” said Dr. Vishnudas. “We are excited to share the progress we made with our E2 program in the neurology space such as Huntington’s disease and Alzheimer’s disease as well as potential oncology indications.”
In addition to utilizing E2s, the BPGbio’s protein homeostasis program features a proprietary library of more than 1,000 Ro3 fragments discovered by BPGbio that are potential ligands and seed compounds to a variety of E2 targets, proprietary ternary structures, a computational tool kit for E2 ligand design, and assays for rapidly attaining selectivity and specificity.
